Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.33 |
| ▸ | ACP1 | P24666 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | LDHA | P00338 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL704145 | 0.87 | CA4 (0.37) | ALDH1A1MAPK1TSHR | |
| SCHEMBL27600931 | 0.84 | CA4 (0.46) | ALDH1A1KDM4ETDP1KMT2ALMNA | |
| SCHEMBL7096596 | 0.82 | ESR2 (0.46) | ALDH1A1KDM4ETDP1KMT2ALMNA | |
| SCHEMBL20594005 | 0.82 | — | — | |
| SCHEMBL7424773 | 0.82 | MAOA (0.44) | ALDH1A1TDP1MAPK1TSHRKMT2A | |
| SCHEMBL17233741 | 0.82 | SMN1; SMN2 (0.46) | ALDH1A1KDM4ETDP1KMT2ALMNA | |
| SCHEMBL754087 | 0.81 | TRPA1 (0.41) | ALDH1A1TSHR | |
| SCHEMBL4470099 | 0.81 | MAOB (0.42) | ALDH1A1KDM4EMAPK1ABCG2KMT2A | |
| SCHEMBL29910455 | 0.81 | MAOB (0.42) | ALDH1A1KDM4EMAPK1ABCG2KMT2A | |
| SCHEMBL4626091 | 0.79 | ALDH1A1 (0.35) | ALDH1A1KDM4ETDP1MAPK1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114835742-A | Fluorescent probe for detecting fluorine ions and preparation method and application thereof | 上海应用技术大学 | 2022-08-02 | — | — | CN | claimed |
| CN-114835742-A | Fluorescent probe for detecting fluorine ions and preparation method and application thereof | 上海应用技术大学 | 2022-08-02 | — | — | CN | disclosed |
| EP-0877607-B1 | BIPHENYL COMPOUNDS AND USE THEREOF AS OESTROGENIC AGENTS | AVENTIS PHARMA SA (FR) | 2006-11-15 | — | — | EP | disclosed |
| US-6794415-B2 | Biphenyl compounds and their use as oestrogenic agents | AVENTIS PHARMA S.A. (FR) | 2004-09-21 | — | — | US | disclosed |
| US-20040043993-A1 | Biphenyl compounds and their use as oestrogenic agents | AVENTIS PHARMA S.A. | 2004-03-04 | — | — | US | disclosed |
| US-6563008-B2 | Treatment of disorders linked to hypofolliculinemia and of certain estrogen-dependent pathologies such as prostatic adenomas or carcinomas, and of benign tumours of the breast | AVENTIS PHARMA S.A. (FR) | 2003-05-13 | — | — | US | disclosed |
| US-20020156324-A1 | BIPHENYL COMPOUNDS AND THEIR USE AS OESTROGENIC AGENTS | AVENTIS PHARMA S.A. | 2002-10-24 | — | — | US | disclosed |
| US-6448294-B1 | SUCH AS 1,5-DICHORO- OR 5-(4-(2-(DIMETHYLAMINO)ETHOXY)PHENYL) SUBSTITUTED -6-(4-HYDROXYPHENYL)-2-NAPHTHALENOLS; ANTIUTERO-TROPHIC AND REPLACEMENT TREATMENT OF SYMPTOMS LINKED TO MENOPAUSE PARTICULARLY OSTEOPOROSIS | AVENTIS PHARMA S.A. (FR) | 2002-09-10 | — | — | US | disclosed |
| US-20020068736-A1 | Biphenyl compounds and their use as oestrogenic agents | LESUISSE DOMINIQUE (FR) | 2002-06-06 | — | — | US | disclosed |
| EP-0880496-B1 | BIPHENYL COMPOUNDS AND USE THEREOF AS OESTROGENIC AGENTS | AVENTIS PHARMA SA (FR) | 2002-05-29 | — | — | EP | disclosed |
| US-6147119-A | TREATING HYPOFOLLICULINIA DISORDERS; ANTICARCINOGENIC, ANTIMETASTASIS AND ANTITUMOR AGENTS; PREMENSTRUAL TENSION, MENOPAUSE, OSTEOPOROSIS | HOECHST MARION ROUSSEL (FR) | 2000-11-14 | — | — | US | disclosed |
| EP-0757982-B1 | Biphenylic compounds, process for their preparations and intermediates for this process, their use as 5-alpha-reductase inhibitors and pharmaceutical compositions containing them | HOECHST MARION ROUSSEL INC (FR) | 2000-09-20 | — | — | EP | disclosed |
| US-5965763-A | Biphenyl compounds | HOECHST MARION ROUSSEL (FR) | 1999-10-12 | — | — | US | disclosed |
| US-5630962-A | 2-Fluoropyridines, their preparation and their use in liquid crystal mixtures | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-05-20 | — | — | US | disclosed |
| US-5629428-A | 3-Chloropyridines, and their use in liquid-crystal mixtures | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-05-13 | — | — | US | disclosed |
| EP-0757982-A1 | Biphenylic compounds, process for their preparations and intermediates for this process, their use as 5-alpha-reductase inhibitors and pharmaceutical compositions containing them | ROUSSEL UCLAF (FR) | 1997-02-12 | — | — | EP | disclosed |
| US-5445763-A | Ferroelectricity; switching and/or display devices containing outer plates, electrodes, at least one polarizer and one alignment layer | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-08-29 | — | — | US | disclosed |
| US-5232916-A | Inhibitors of leukotriene synthesis | MERCK FROSST CANADA, INC. (CA) | 1993-08-03 | — | — | US | disclosed |
| US-5102881-A | Leukotriene biosynthesis inhibitor | MERCK FROSST CANADA, INC. (CA) | 1992-04-07 | — | — | US | disclosed |
| EP-0349062-A1 | Quinoline ether alkanoic acid | MERCK FROSST CANADA INC. (CA) | 1990-01-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068736-A1 | Biphenyl compounds and their use as oestrogenic agents | ESR2, ESR1, CYP19A1 | ALDH1A1 381/4885KDM4E 342/4885TDP1 4524/4885 |
| US-20020156324-A1 | BIPHENYL COMPOUNDS AND THEIR USE AS OESTROGENIC AGENTS | SHBG, ESR2, CYP19A1 | ALDH1A1 176/4885KDM4E 2009/4885TDP1 3294/4885 |
| US-20040043993-A1 | Biphenyl compounds and their use as oestrogenic agents | CYP19A1, HSD17B11, GPER1 | ALDH1A1 272/4885KDM4E 1103/4885TDP1 3945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.